Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Recruiting now · Phase 1

Conditions studied: Hidradenitis Suppurativa

In brief

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Key facts

Study ID

NCT07049575

Run by

Incyte Corporation

People needed

24

Starts

2025-11-03

Expected to finish

2026-12-09

Last updated by the study team

2026-08-06

Who can join

Age: 12 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HS for at least 6 months before screening visit.
• Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
• Total estimated treatment BSA > 20% at screening and baseline.
• Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
• Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
• Further inclusion criteria apply.

You may not qualify if…

• Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
• Laboratory values outside of the protocol-defined ranges.
• Further exclusion criteria apply.

Where it is running

• Paddington Testing Co Inc — Philadelphia, Pennsylvania, United States (enrolling)
• Unity Clinical Research — Oklahoma City, Oklahoma, United States (enrolling)
• Saguaro Dermatology — Phoenix, Arizona, United States (enrolling)
• Amicis Research Center Valencia — Northridge, California, United States (enrolling)
• Children'S Hospital of Orange County — Orange, California, United States (enrolling)
• Clinical Trials Research Institute — Thousand Oaks, California, United States (enrolling)
• Clarity Dermatology — Castle Rock, Colorado, United States (enrolling)
• International Clinical Research Tennessee Llc — Sanford, Florida, United States (enrolling)
• Lenus Research Medical Group, Llc — Sweetwater, Florida, United States (enrolling)
• Trueblue Clinical Research — Tampa, Florida, United States (enrolling)
• Lane Dermatology and Dermatologic Surgery — Columbus, Georgia, United States (enrolling)
• Options Research Group, Llc — West Lafayette, Indiana, United States (enrolling)
• Equity Medical, Llc — Bowling Green, Kentucky, United States (enrolling)
• Delricht Research — Baton Rouge, Louisiana, United States (enrolling)
• Revival Research Institute, Llc Troy — Troy, Michigan, United States (enrolling)
• Red River Research Partners — Bolivar, Missouri, United States (enrolling)
• Dr Bobby Buka, Md Greenwich Village — New York, New York, United States (enrolling)
• Equity Medical, Llc — New York, New York, United States (enrolling)
• Red River Research Partners — Fargo, North Dakota, United States (enrolling)
• First Oc Dermatology — Fountain Valley, California, United States
• Centricity Research Columbus — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.